Personalized cell therapy combination achieves complete remission in CLL patients

Via Top Health News -- ScienceDaily

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research.

View original post here:

%d bloggers like this: